We haven’t heard back from Auxly on this yet. Our initial analysis seems to hold, and we’ve looked at this from several directions. It appears to stem from a booking to ‘Biological Assets’ in their 3rd quarter.
By all appearances, it looks like an accounting error. If so, a restatement might not be far behind.
Perhaps we’ve missed something. We’ll let you know as soon as we get a response.
The preceding is the opinion of the author, and is in no way intended to be a recommendation to buy or sell any security or derivative. The author holds no position in $XLY